Monday, 16 September 2019
Subscribe to our RSS Feed
Subscribe
Want to Receive News & Updates from AHDB?
Stay up to date on the latest information you need to devise benefit designs, make coverage decisions, and further value-based healthcare! Sign up for our newsletter or print publications today by entering your contact information below and clicking "Subscribe".
First Name *
Last Name *
Email Address *
Email Address (Verify) *
We will request your mailing address on the next page.
 
American Health & Drug Benefits
  • Home
  • Issues
    • 2019
      • June/July 2019 Vol 12, No 4
      • May 2019 Vol 12, No 3
      • April 2019 - Vol 12 No 2
      • February 2019 - Vol 12 No 1
    • 2018
      • December 2018 Vol 11, No 9
      • November 2018 Vol 11, No 8
      • October 2018 Vol 11 No 7
      • September 2018 Vol 11, No 6
      • July 2018 - Vol 11 No 5
      • June 2018 - Vol 11 No 4
      • May 2018 - Vol 11 No 3
      • April 2018 - Vol 11 No 2
      • February 2018 - Vol 11 No 1
    • Issue Archive
    • Value-Based Care in Cardiometabolic Health
  • Special Issues
    • Supplements
    • 2019 Special Issues
      • August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights
      • 2019 Payers' Guide Mid-Year Addendum
      • March 2019 Vol 12, Tenth Annual Payers' Guide
      • January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights
      • February 2019 - Vol 12 No 1 Supplement 1: Budget Impact of Omadacycline for the Treatment of Patients with Community-Acquired Bacterial Pneumonia in the United States from the Hospital Perspective
      • February 2019 - Vol 12 No 1 Supplement 2: Budget Impact Model of Omadacycline on Replacing a Proportion of Existing Treatment Options Among Patients Who Present to the Emergency Department with Acute Bacterial Skin and Skin Structure Infections
    • Special Issue Archive
  • For Authors
    • Call for Papers
    • Submit a Manuscript
    • Instructions for Authors
    • Join Peer Review
    • Permissions
  • Topics
    • Journal Topics
    • Web Exclusive Topics
  • Web Exclusives
    • All Web Exclusives
    • Select Drug Profiles
    • FDA Approvals
    • In the News
    • Press Releases
    • Videos
  • Conference Correspondent
    • ASCO 2019 - Chronic Lymphocytic Leukemia
    • ASH 2018 - CLL
    • ID Week 2018
    • ASH 2017 - CLL
    • ACR 2017 - Rheumatoid Arthritis
    • ASCO 2017 - Chronic Lymphocytic Leukemia
    • ASCO 2017 - Acute Myeloid Leukemia
    • ASH 2016 - Multiple Myeloma
    • ASH 2016 - Chronic Lymphocytic Leukemia
  • About
    • About AHDB
    • About Engage HC
    • Contact Us
    • Editorial Policies
    • Peer-Review Process
    • Editorial Board
    • Editorial Process
    • Advertising Contacts
    • Advertising Policy
    • Reprints
    • Glossary

Catherine T. Piech, MBA

Ms Piech is Vice President at Health Economics and Outcomes Research, Centocor Ortho Biotech Services, LLC, Horsham, PA.

Authored Items
Effectiveness of Anti-Tumor Necrosis Factor Agents in the Treatment of Rheumatoid Arthritis: Observational Study
Anna D’Souza, PhD, Matthew Mitchell, PharmD, MBA, FAMCP, Brian L. Meissner, PharmD, PhD, Boxiong Tang, MD, PhD, Scott McKenzie, MD, Catherine T. Piech, MBA
July/August 2010, Vol 3, No 4 in Clinical
Health Plan Retention and Pharmacy Costs of Newly Diagnosed Patients with Chronic Kidney Disease in a Managed Care Population
Maureen Kubacki, PharmD, MBA , Jeff Januska, PharmD, Chureen Carter, PharmD, MS , Alan D. L. Herrera, PharmD, Jim Wang, PhD, Janice M.S. Lopez, PharmD, MPH, Catherine T. Piech, MBA
November/December 2009, Vol 2, No 7 in Business
Last modified: September 6, 2013
  • Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME
  • Home
  • About
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Advertising Policy
Copyright © 2019 Engage Healthcare Communications, LLC. All rights reserved.